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Abstract
Underestimated for a long time, the involvement of the microenvironment has been
proven essential for a better understanding of the cancer development. In keeping with
this, the tumor is not considered anymore as a mass of malignant cells, but rather as an
organ composed of various malignant and nonmalignant cell populations interacting
with each other to create the tumor microenvironment. The tumor immune contexture
plays a critical role in shaping the tumor immune response, and it is now well supported
that such an immune response is impacted by the hypoxic stress within the tumor
microenvironment. Tumor hypoxia is closely linked to tumor progression, metastasis,
treatment failure, and escape from immune surveillance. Thus, hypoxia seems to be a
key factor involved in creating an immune-suppressive tumor by multiple overlapping
mechanisms,  including the  impairment  of  the  function  of  cytotoxic  immune cells,
increasing  the  immunosuppressive  properties  of  immunosuppressive  cells,  and
activating resistance mechanism in the tumor cells. In this chapter, we review some
recent findings describing how hypoxic stress in the tumor microenvironment hijacks
the antitumor immune response.
Keywords: cancer, hypoxia, immune response, tumor microenvironment, autophagy,
tumor plasticity, tumor heterogeneity
1. Introduction
Malignant cells are part of cellular and microenvironmental complexes which both define the
initiation, progression, and maintenance of the malignant phenotype. In turn, malignant cells
participate in creating a hostile microenvironment characterized by hypoxic areas within the
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tumors. Indeed, the oxygen level in the hypoxic tumor is usually lower than that of corresponding
normal tissue. The oxygenation level of tumor is likely depending on (i) the initial oxygenation
of the tissue; (ii) the degree of the tumor heterogeneity; (iii) the tumor size and stage. Table 1
summarizes the percentage of oxygen level reported as a median in some healthy organs and
their corresponding tumors, as defined by several studies.




Kidney cortex/renal cancer 7.0/1.3
Liver/liver cancer 4.0–7.3/0.8
Lung/nonsmall cell lung carcinoma 5.6/2.2
Pancreas/pancreatic tumor 7.5/0.3
Rectal mucosa/rectal carcinoma 3.9/1.8
Table 1. Comparison of the percentage (%) of oxygen level in different healthy tissues and in their corresponding
cancers.
It is now widely appreciated that hypoxia is one of the most relevant factor involved in the
impairment of the antitumor immune response by damping the cytotoxic function of immune
cells. There are numerous studies supporting that hypoxic stress leads to the establishment of
immune tolerance of tumor cells by preventing the migration and the homing of immune
effector cells into established tumors. Furthermore, hypoxia can also drive tumor cell plasticity
and functional heterogeneity and, thus, favors the emergence of more aggressive tumors.
Many strategies are emerging for targeting intratumor hypoxia in order to change the
immunosuppressive properties of the tumor to a microenvironment able to support antitumor
immunity.
2. Hypoxia is the major factor of the tumor microenvironment
The long-lasting tumor immunology research has validated the concept of tumor immuno-
surveillance. The tumor immunosurveillance consists in the fact that cytotoxic immune cells
recognize nascent transformed cells and destroy them before they become clinically apparent.
Several types of immune cells are involved in the control of tumors such as immune effector
and immune suppressor cells. Thus, cytotoxic T lymphocytes (CTL) belong to the adaptive
immune system and they are able to recognize tumor antigens through the T-cell receptor
(TCR) [1]. The antigens expressed exclusively by tumor cells are called tumor-specific anti-
gens [2]. In addition to CTL, the tumor immune surveillance involves natural killer (NK) cells
that belong to the innate immune system [1]. NK cells recognize tumor cells by mechanisms
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called “missing-self” and “induced-self” [3]. Briefly, NK cells are regulated by a balance of
inhibitory and activating signals of surface receptors. Thus, NK cells can kill their target cell
depending on the recognized ligand(s). The identification of activating or inhibitory ligands
allows NK cells to distinguish between “self” versus “nonself” and “self” versus “altered self”
by “missing-self” and “induced-self” recognitions. Indeed, the protection of normal cells from
NK cell killing is achieved by balancing the stimulatory signals delivered by stimulatory
ligands with inhibitory signals delivered by self MHC class I molecules. When the expression
of self MHC class I molecules is lost following cell transformation or infection, the stimulatory
signals delivered by the target cell remain unbalanced, leading to the activation of NK cells
and lysis of target cells (known as missing-self recognition). Under some circumstances,
transformed or infected cells overexpress stimulatory ligands that overcome the inhibitory
signals leading to target cell lysis (known as induced-self recognition). It has been reported
that both missing-self and induced-self recognition could operate simultaneously. In this case,
NK cells display a high ability to discriminate between normal and transformed target cells [4].
In addition to cytotoxic immune cells, the tumor immune contexture contains immune
suppressive cells such as myeloid-derived suppressor cells (MDSC) able to inhibit the function
of immune effectors. Macrophages and neutrophil granulocytes are also involved in antitumor
immunity [5]. These cells display tumor antigens and can stimulate other immune cells such
as CTL, NK cells, or antigen-presenting cells (APC) [6]. Although both CTL and NK cells kill
their target following the establishment of immunological synapse (IS) [7], the molecular
mechanism by which they recognize their target tumor cells is fundamentally different. Two
major pathways are used by CTL and NK cells to recognize and destroy tumor cells: (i) through
the release by immune cells of cytotoxic granules containing perforin and granzymes and these
cytotoxic granules are captured by tumor cells to induce cell death by apoptosis [8], and (ii)
through tumor necrosis factor (TNF) superfamily-dependent mechanism [9].
It has been proposed that despite the powerful ability of the immune system to attack cancer
cells, tumors can outmaneuver the immune effectors cells and escape the immune surveillance.
It is now well documented that the ability of tumor cells to escape immune cell control is most
likely resulted from the activation of several resistance mechanisms to evade effective and
functional host immune response. Therefore, it stands to reason that established tumors,
displaying multiple resistance mechanism, are likely not fully controlled by the immune
system. In keeping with this, it is strongly believed that clinically detected cancers have most
likely evaded effective antitumor immune responses. Recently, it has been reported that in
addition to its role in protecting host against tumor development, the immune system can
under certain circumstances sculpt the immunogenic phenotype of well-developed tumors.
Such a mechanism favors the emergence of resistant tumor cell clones [10]. Accumulating
experimental and clinical evidence suggest that the resistance mechanisms activated in tumor
cells are multifactorial and that such resistance mechanisms are primarily evolved and
activated in the tumor microenvironment [11]. It appears that hypoxia is the major tumor
microenvironmental factor involved in the alteration of the transcriptome and the metabolome
of tumor cells as well as their proliferation, survival, and invasion [12].
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In this chapter, we summarize some recent findings describing how hypoxic stress in the tumor
microenvironment regulates the antitumor immune response and leads to tumor escape from
immunosurveillance. We focus on how hypoxia confers resistance to immune attack and
impairs tumor cell killing mediated by CTL and NK cells.
2.1. Hypoxia and hypoxia-inducible factors (HIF) regulation
Tumor cells are able to adapt to hypoxic stress through the regulation of the hypoxia inducible
factor family of transcription factors (HIFs) [13]. It has been reported for a large number of
human cancers that HIFs were overexpressed and such overexpression is associated with poor
response to treatment [14]. Moreover, evidence showed a clear positive correlation between
enhanced hypoxic expression of HIFs and mortality [13]. Therefore, inhibition of HIFs could
represent a novel approach to improve cancer therapies. Currently, efforts are being actively
pursued to identify inhibitors of HIFs and to test their efficacy as anticancer therapeutics.
Three isoforms of HIF have been identified: HIF-1, HIF-2, and HIF-3. The hypoxia-inducible
factor-1 (HIF-1) is the major factor mediating adaptive responses to changes in tissue oxygen
level [15]. Indeed, HIF-1 is a heterodimer composed of a constitutively expressed HIF-1β subunit
and an O2-dependent regulated HIF-1α subunit. HIF-1α is a DNA-binding basic helix-loop helix
of the PAS family [Per (period circadian protein); Arnt (aryl hydrocarbon receptor nuclear
translocator protein); Sim (single-minded protein)] [16]. HIF-1α contains two oxygen-depend-
ent degradation domains (ODDD), one in the N-terminal (N-ODDD) moiety and one in the C-
terminal moiety (C-ODDD) [17, 18]. It also contains two transactivation domains (TADs), one
N-terminal, which overlaps with the C-ODDD, and one C-terminal [19].
2.2. Regulation of HIF-1 level
The expression level of HIF-1α is determined by the rates of protein synthesis and protein
degradation. While the synthesis of HIF-1α is regulated in an O2-independent manner, its
degradation is primarily regulated via an O2-dependent mechanism. Thus, normoxic cells
constantly synthesize HIF-1α protein and degrade it rapidly [17]. It has been shown that under
normoxic conditions HIF-1α has a short half-life of less than 5 min [20]. However, under
hypoxia or low oxygen level, the degradation of HIF-1α is blocked or dramatically decreased
[21]. Under normoxia, HIF-1α is hydroxylated on proline residue 402 and/or 564 in the ODDD
by prolyl hydroxylase domain protein 2 (PHD2) [17, 22]. Such oxygen-dependent hydroxyla-
tion of HIF-1α results in its binding to the von Hippel-Lindau tumor suppressor protein
(pVHL). pVHL is the recognition component of an E3 ubiquitin-protein ligase complex that
targets HIF-1α for proteolysis by the ubiquitin-proteasome pathway [23].
Enzymes regulating HIF-1α proteasomal degradation were first identified to be related to egl-9
in caenorhabditis elegans and to termed prolyl hydroxylase domain (PHD) enzymes (PHD1,
PHD-2, and PHD3) [24, 25]. PHD2 uses oxygen as a substrate, and thus, its activity is inhibited
under hypoxic conditions [25]. The inhibition of PHD2 leads to the inhibition of prolyl
hydroxylation of HIF-1α and subsequently to the inhibition of HIF-1α-dependent proteasomal
degradation. Consequently, HIF-1α rapidly accumulates in the cytoplasm, translocates to the
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nucleus and dimerizes with HIF-1β. The HIF-1α/HIF-1β heteromeric dimer binds to the
hypoxia responsive element (HRE) in target genes, recruits coactivators and activates tran-
scription [14] (Figure 1A).
Figure 1. The role of hypoxic stress in the impairment CTL and NK-cell mediated lysis. (A) Under normoxia, the oxy-
gen-sensitive prolyl hydroxylase domain protein 2 (PHD2) hydroxylates HIF-1α subunit. Hydroxylated HIF-1 interact-
ed with Von Hippel-Lindau protein (VHL), subjected to ubiquitination and subsequently degraded by the ubiquitin-
proteasome system. Under hypoxic stress, the function of PHD2 protein is blocked, HIF-1α is therefore stabilized and
translocated to the nucleus to form heterodimeric complex with HIF-1β to transcriptionally induce the expression of
HIF-target genes involved in several pathways such as autophagy. (B) Under hypoxia, STAT3 is phosphorylated at
Ser-705 residue in a HIF-dependent manner by a mechanism which is not fully understood. (C) The hypoxia-depend-
ent induction of autophagy leads to the degradation of the adaptor protein p62/SQSTM1, involved in targeting phos-
pho-STAT3 to the ubiquitin proteasome system for degradation. Thus, targeting autophagy accumulated p62/SQSTM1
and therefore accelerated the degradation of phospho-STAT3. The degradation of phospho-STAT3 restores CTL-medi-
ated lysis of tumor cells. In addition, the induction of autophagy in hypoxic tumor cells leads to the selective degrada-
tion of granzyme B (GZMB), a serine protease released by natural killer (NK) cells and contained in the cytotoxic
granules. Such degradation inhibits NK-mediated lysis of tumor cells.
Using genomewide chromatin immunoprecipitation combined with DNA microarray (ChIP-
chip) or DNA sequencing (ChIP-seq) analysis, it has been shown that more than 800 genes
involved in several cell functions are direct targets of HIF [26, 27]. HIF-1 activates the
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expression of these genes by binding to a 50 base pair cis-acting HRE located in their enhancer
and promoter regions [28]. The HREs of all these genes contain the core sequence 5′-[A/
G]CGT-3′, which in most cases is ACGTG [29]. It has been reported that HIF transcription
factors preferentially bind to specific bases in the 5′ and 3′ proximity of the core that has led
to define the following HRE consensus sequence [T/G/C][A/G]CGTG[CGA][GTC][GTC]
[CTG] [29].
Similar to HIF-1α, the stabilization of HIF-2α is also regulated by oxygen-dependent hydrox-
ylation [30]. This could be related to the fact that HIF-1α and HIF-2α displayed a similar
structure of their DNA binding and dimerization domains. However, the major difference
between the structure of HIF-1α and HIF-2α is in their transactivation domains [31]. In terms
of genes expression, both HIF-1α and HIF-2α share overlapping target genes, and each one
also regulates a set of unique targets [32].
In sharp contrast with HIF-1α and HIF-2α, HIF-3α lacks the transactivation domain and could
function as an inhibitor of HIF-1α and HIF-2α. It has been reported that the expression of
HIF-3α is regulated by HIF-1 [33]. In addition to the regulation of the expression of a large
number of genes, HIF family members regulate hypoxia-related microRNAs (HRM) [34] and
some chromatin modifying enzymes [35].
3. Intra-tumor hypoxia: a key feature that triggers several resistance
mechanisms of tumor evasion from immune surveillance
It has been clearly established that the immune effector activity and the antitumor immune
response are significantly regulated by hypoxia. Indeed, hypoxia, via HIF-1α, decreases the
susceptibility of lung cancer cells to CTL-mediated killing. It appears that the resistance to CTL
is related to the effect of HIF-1α to induce the phosphorylation of signal transducer and
activator of transcription 3 (STAT3) in tumor cells by a mechanism involving the vascular
endothelial growth factor (VEGF) secretion. These data suggest that following its translocation
to the nucleus, HIF-1α cooperates with pSTAT3 to impair lung carcinoma cell susceptibility to
CTL-mediated killing [36] (Figure 1B). More recently, it has been shown that the expression of
the phosphorylated form of STAT3 at Ser-705 residue is tightly controlled by the induction of
autophagy in hypoxic tumor cells as the accumulation of pSTAT3 was no longer observed when
autophagy was targeted genetically in tumor cells [37]. Autophagy is a catabolic cell degra-
dation process. Autophagy plays an essential role in preventing accumulation of altered cell
components [38] and as an adaptive metabolic response to provide nutrients. Recently, an
unexpected role of autophagy in shaping the antitumor immune response [39] and the
acquisition of resistance to TNFα has been shown [40]. Autophagy is activated under stress
conditions such as hypoxia, nutrient starvation, growth factor withdrawal, and endoplasmic
reticulum stress. It has been reported that the molecular mechanism by which autophagy
regulates the pSTAT3 level involves the protein p62/SQSTM1 the ubiquitin proteasome
system [37, 41].
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Another study showed that in addition to the mechanism described earlier, it has been shown
that the stem cell self-renewal transcription factor NANOG is also involved in the regulation
of CTL-mediated tumor cell lysis [42, 43]. Hypoxia regulates NANOG at both transcriptional
and translational levels and targeting NANOG in hypoxic cells restored CTL-mediated tumor
cell killing. Furthermore, NANOG depletion results in the inhibition of STAT3 phosphoryla-
tion and its nuclear translocation. The hypoxia-induced microRNA (miR)-210 is also involved
in the regulation of CTL-mediated tumor cells lysis. In fact, HIF-1 induces the expression of
miR-210 which subsequently targets nonreceptor protein tyrosine phosphatase type 1
(PTPN1), homeobox A1 (HOXA1), and tumor protein p53-inducible protein 11 (TP53I11), and
thereby decreases tumor cell susceptibility to CTL [44]. In the context of NK-mediated tumor
cell lysis, it has been described that hypoxia increases the shedding of the major histocompat-
ibility complex (MHC) class I polypeptide-related sequence A (MICA), a ligand for the
activating receptor natural killer group 2 member D (NKG2D), on the surface of prostate cancer
cells leading to an impairment of NO signaling [45] and subsequent escape of tumor cells from
NK- and CTL-mediated killing. MICA expression is also downregulated by HIF-1 in osteo-
sarcoma cells resulting in tumor resistance to NK-mediated lysis [46]. Through the activation
of autophagy, it has been recently reported that melanoma and breast tumor cells escape NK-
mediated lysis and that targeting autophagy in hypoxic tumor cells was sufficient to restore
NK-mediated lysis. In this study, it has been shown that the activation of autophagy under
hypoxia was responsible for the degradation of NK-derived granzyme B making hypoxic
tumor cells less sensitive to NK-mediated killing [39, 47, 48] (Figure 1C). In line with the studies
described earlier, it is now well admitted that hypoxic stress in the tumor microenvironment
is a key factor involved in the control of antitumor immune response. Beside its role in
impairing the function of cytotoxic immune cells, the immunosuppressive effect of hypoxia
contributes to the emergence of resistant tumor cells that compromise the effectiveness of the
anti-tumor immune response [49].
4. Hypoxia and tumor cell heterogeneity and plasticity
Solid tumors frequently reveal pronounced tumor cell heterogeneity with regards to cell
organization, cell morphology, cell size, and nuclei morphology [50]. The molecular mecha-
nisms underlying the phenotypic heterogeneity involve genetic, epigenetic, and environmen-
tal factors. It is now well established that hypoxia is an important contributor to intra- and
intertumor cell heterogeneity [15, 51] by altering the expression of specific genes involved in
cellular phenotype. In this respect, it has been reported that neuroblastoma cells and breast
cancer cells lose their differentiated gene expression patterns and develop stem cell-like
phenotypes under hypoxic stress [52, 53]. As a low stage of differentiation in neuroblastoma
and breast cancer is associated with poor prognosis, it is strongly believed that, in addition to
its contribution to tumor heterogeneity, hypoxia-dependent induction of tumor cell dediffer-
entiation contributes to tumor cell plasticity and aggressiveness.
Several lines of evidence suggest that tumor microenvironment drives stem cell renewal and
differentiation. Indeed, poorly vascularized tumors contain hypoxic regions with undifferen-
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tiated ‘stem-like’ tumor cells that survive under control of HIFs [54]. It has been reported that
hypoxic stress in colon cancer inhibits the differentiation of tumor cells and maintains their
stem-like phenotype [55]. In addition, myofibroblasts stromal cells secrete factors involved in
maintaining cancer stem cells (CSC) population in colon cancer [56]. Furthermore, stromal cells
drive a CSC phenotype on differentiated cancer cells, allowing a transient morphological
heterogeneity observed in several cancers. In this regard, transient phenotypic changes from
epithelial to mesenchymal (epithelial-mesenchymal transition (EMT)) or mesenchymal to
epithelial (mesenchymal to epithelial transitions (MET)) phenotype, are initially considered as
conversions facilitating cell plasticity but have recently gained appreciation as events involved
in tumor heterogeneity [57]. In the context of tumor immunity, recent evidence revealed that
tumor cell plasticity has serious implications in terms of immunological recognition and killing
of the tumor, since such tumor cell plasticity may lead to the emergence of immunoresistant
variants [58].
Although the role of the immune system in inhibiting early stages of tumor growth is well
established, it is now strongly suggested that the immune system can also facilitate the
advanced stages of tumor progression by sculpting the immunogenic phenotype of a devel-
oping tumor to favor the emergence of immune-resistant tumor cell variants. This has led to
the concept of “immunoediting” which encompasses three phases: elimination, equilibrium,
and escape. Thus, immunoediting allows tumors to evade immune destruction by becoming
less immunogenic or more immunosuppressive [59]. Such adaptability, achieved through cell
reprogramming, reflects an important property of tumors called immune-induced plasticity.
While the molecular basis of immune-dependent induction of tumor cell plasticity and its
effective contribution to the selection of tumor aggressive variants is still elusive, recent
findings have revealed that activated CD8+ T cells can stimulate mammary epithelial tumor
cells to undergo EMT and acquire the increased tumorigenic capability and therapy resistance
of breast CSCs [60]. In this regard, it has been shown that reciprocal interactions between
melanoma and immune cells enhances tumor cell plasticity and drives therapy resistance [61].
Based on these data, it is now well defined that targeting phenotypic plasticity should be
considered for the development of novel therapeutic strategies with the ultimate goal to
prevent the establishment of a more aggressive phenotype of cancer cells.
5. The clinical significance of targeting hypoxia
For many years, the major issue in the field of cancer immunity was to understand how cancer
cells manage to evade immune surveillance despite the presence of a competent immune
system. To address this issue, the major focus was on the mechanisms by which tumor cells
escape cytotoxic immune cell recognition without considering the impact of the tumor
microenvironment. This could partially explain why despite intense investigation, the gains
provided by immunotherapy until recently are relatively modest. In addition, accumulating
evidence suggests that tumor cell resistance mechanisms are likely evolved in the hypoxic
tumor microenvironment. In keeping with this, it is therefore more accurate to consider cancer
as a disease of the microenvironment rather than a disease of cells. Although remarkable
Hypoxia and Human Diseases356
progresses have been achieved over the past two decades regarding the impact of the tumor
microenvironment in cancer biology and treatment, its contribution in the development of
tumor resistance to immune cell killing remains fragmented.
Emerging data indicates that hypoxia stress within the tumor microenvironment is a key factor
involved in the impairment of the antitumor immune response. [62] Therefore, a deep
understanding of the molecular mechanism by which hypoxia induces tumor resistance may
contribute to the development of more effective tumor immunotherapies.
Consistent with the fact that hypoxia-dependent overexpression of HIF-1α is associated with
an increased patient mortality in several cancer types, it stands to reason that inhibition of
HIF-1 activity in preclinical studies would have marked effects on tumor growth and survival.
In keeping with this, efforts are underway to identify selective inhibitors of HIF-1 and to assess
their efficacy as anticancer therapeutics. Currently, two main approaches are used to target
hypoxia in tumors, namely bioreductive prodrugs, and inhibitors of molecular targets upon
which hypoxic cell survival depends [63, 64]. However, several lines of evidence indicate that
the HIF pathway is technically extremely challenging to target. Indeed, the first evidence is
that transcription factors in general, including HIF, have long been considered “undruggable,”
and therefore, no specific inhibitor of HIF has been brought to the market so far. The second
evidence is that multiple levels of regulation and signaling pathways converge on and emerge
from HIF [65]. Nevertheless, based on the molecular mechanism of HIF-1 protein, it has been
suggested that small molecules could be used to inhibit HIF-1 activity through a variety of
mechanisms including inhibition of (i) HIF-1α protein synthesis; (ii) HIF-1α protein stabiliza-
tion; (iii) HIF-1α/β dimerization, and (iv) HIF-1/DNA binding. Two comprehensive recent
reviews summarize these mechanisms in detail and give fairly exhaustive lists of the small-
molecule inhibitors for each level [15, 66].
Using a cell-based assay, several small-molecule inhibitors of HIF-1 activity have been
identified. Briefly, topoisomerase I inhibitors block the expression of HIF-1α via an undefined
mechanism [67]. The small molecule YC-1 (3-(5′-hydroxy-methyl-2′-furyl)-1-benzylindazole)
was also shown to reduce the level of HIF-1α by a mechanism that has not been established
but at least is known to work independently from its function as a stimulator of soluble
guanylate-cyclase activity [68]. YC-1 is not in clinical use. The HSP90 inhibitor 17-allyl-
aminogeldanamycin (17-AAG) has been reported to induce the degradation of HIF-1α in a
VHL-independent manner [69–71]. PX-12 (thioredoxin-1 redox inhibitor) and PX-478 are both
inhibitors of HIF-1α protein expression and HIF-1-mediated transactivation [72, 73]. Finally,
the disruptor of microtubule polymerization 2-methoxyoestradiol (2ME2) is able to decrease
the expression of HIF-1α. Currently, only topoisomerase I inhibitors, camptothecin and
topotecan, are clinically approved agents, PX-478, 2ME2, and 17-AAG are under evaluation in
clinical trials, whereas YC-1 and thioredoxin-1 inhibitors are not in clinical use.
Despite of the anticancer effects of these agents could be related, in part, to their inhibition of
HIF-1, it seems that none of these drugs specifically targets HIF-1. Although such lack of
selectivity does not disqualify these drugs as anticancer agents, it enhances the difficulty to
correlate molecular and clinical responses in patients. Therefore, the identification of more
selective HIF-1 inhibitors in the near future is required and more investigation needs to be
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done to identify novel potent and more specific inhibitors targeting clearly defined points in
the HIF pathway.
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